Treatment-related restoration of langerhans cell migration in psoriasis

Journal of Investigative Dermatology

Volumn 134, Issue 1, 2014, Pages 268-271

  Shaw, Frances L ^a   Mellody, Kieran T ^a   Ogden, Stephanie ^a   Dearman, Rebecca J ^a   Kimber, Ian ^a   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; CYCLOSPORIN A; ETANERCEPT; FUMARIC ACID; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; LYMPHOTOXIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ADULT; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDERMIS CELL; EX VIVO STUDY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; LANGERHANS CELL; LETTER; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SKIN BIOPSY; SYSTEMIC THERAPY; T LYMPHOCYTE;

EID: 84890990103     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.289     Document Type: Letter

References (14)

1. Bond E, Adams WC, Smed-Sörensen A et al. (1999) Techniques for time-efficient isolation of human skin dendritic cell subsets and assessment of their antigen uptake capacity. J Immunol Methods 348: 42-56
2. Cumberbatch M, Dearman RJ, Kimber I (1997) Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin- 1 beta for migration. Immunology 92: 388-95
3. Cumberbatch M, Bhushan M, Dearman RJ et al. (2003) IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol 132: 352-9
4. Cumberbatch M, Singh M, Dearman RJ et al. (2006) Impaired Langerhans cell migration in psoriasis. J Exp Med 203: 953-60
5. de Gruijl TD, Sombroek CC, Lougheed SM et al. (2006) A postmigrational switch among skinderived dendritic cells to a macrophagelike phenotype is predetermined by the intracutaneous cytokine balance. J Immunol 176: 7232-42
6. Ghoreschi K, Bruck J, Kellerer C et al. (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208: 2291-303
7. Gordon KB, Bonish BK, Patel T et al. (2005) The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 153: 945-53
8. Griffiths CEM, Dearman RJ, Cumberbatch M et al. (2005) Cytokines and Langerhans cell mobilisation in mouse and man. Cytokine 32: 67-70
9. Gupta AK, Baadsgaard O, Ellis CN et al. (1989) Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A. Arch Dermatol Res 281: 219-26
10. Menter A, Griffiths CEM (2007) Current and future management of psoriasis. Lancet 370: 272-84
11. Nestle FO, Kaplan DH, JNWN Barker (2009) Psoriasis. N Engl J Med 361: 496-509
12. Ratzinger G, Stoitzner P, Ebner S et al. (2002) Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 168: 4361-71
13. Shaw FL, Cumberbatch M, Kleyn CE et al. (2010) Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. J Invest Dermatol 130: 1940-2
14. Wain EM, Darling MI, Pleass RD et al. (2010) Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol 162: 427-34